In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Peter Charlish

Principal analyst

Surrey, England
Peter originally trained as a pharmacologist and has been following the fortunes of the pharmaceutical and medtech industries for over 35 years. During that time he has interviewed many people, attended many conferences and trade shows, and has visited companies large and small. He has written items for newsletters, feature articles for magazines, as well as longer in-depth reports. He has also spoken on healthcare-related matters at a number of international conferences. Out of all that has come a passion to understand what drives individuals and organisations to push back the frontiers of knowledge for the overall benefit of mankind. In his spare time he likes to complain about falling standards (grammar, manners, road users who don’t indicate), and he has little time for those who use management gobbledegook.
Set Alert for Articles By Peter Charlish

Latest From Peter Charlish

Medtronic’s Deal With Aetna Heralds New Value-Based Era

Medtronic's outcomes-based insulin pump supply deal with Aetna is the latest example of the medtech industry's shift toward value-based care.

Medical Device Diabetic Care

Liquid Biopsy On Course To Transform Cancer Management

Liquid biopsies look set to revolutionize the management of cancer patients.  A significant application could come in immuno-oncology, given the rapid uptake of IO drugs and the need to monitor changes in a patient’s immune profile over time to guide therapy selection.

Cancer Business Strategies

Qiagen's Strategic Alliances, 2012–2017

The January deal with Singulex is just the latest in a long string of Qiagen's tie-ups with pharma and diagnostics partners. Herein, a five-year review of Qiagen's collaborations.

Diagnostics Medical Device

Singulex And Qiagen Partner In Personalized Medicine

Singulex and Qiagen have entered a strategic alliance whereby Qiagen will be able to offer its clients companion diagnostic development services based on Singulex’s Single Molecule Counting technology.

Deals In Vitro Diagnostics

Flatiron Aims To Accelerate, Personalize Cancer Research

Flatiron Health was formed to exploit a previously untapped source of real-world data on the treatment and clinical outcomes of cancer patients. The company is now working with most of the major players in the oncology sector as well as with the FDA to maximize the benefits of such data analytics.

BioPharmaceutical Innovation

CGT Catapult Builds Cell/Gene Manufacturing Facility

The CTG Catapult aims to capture the commercial potential of the UK's cell and gene therapy research. To that end, it has constructed a GMP-compliant manufacturing facility in Stevenage.

See All